pancreatitis and glp-1 Agonists Risk Frontiers | GLP-1 Receptor Agonists:
Description
Saving muscle while losing weight: a vital strategy for sustainable results while on GLP-1 related drugs
More research with Phase III trials is warranted in order to further consolidate these findings across different T2DM subpopulations
Lifestyle changes are the foundation of long-term weight control, even for those on prescription weight-loss medications
Retatrutides Phase 2 data also demonstrated robust improvements in blood pressure, fasting glucose, and triglycerides
LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept
The Loss of Exclusivity (LOE) of semaglutide in China, Brazil, Canada and India in 2026 will result in the availability of cheaper generics in these countries (and possibly neighbouring countries via parallel import)
